Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice

Varování

Publikace nespadá pod Ústav výpočetní techniky, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Autoři

ŽÁČKOVÁ Daniela KLAMOVA Hana BELOHLAVKOVA Petra STEJSKAL Lukas NEČASOVÁ Tereza SEMERÁD Lukáš WEINBERGEROVÁ Barbora SRBOVA Dana VOGLOVA Jaroslava ČIČÁTKOVÁ Petra ŠUSTKOVÁ Zuzana HORŇÁK Tomáš BARANOVÁ Jana PROCHÁZKOVÁ Jiřina MAYER Jiří

Rok publikování 2021
Druh Článek v odborném periodiku
Časopis / Zdroj LEUKEMIA & LYMPHOMA
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://www.tandfonline.com/doi/full/10.1080/10428194.2020.1827242
Doi http://dx.doi.org/10.1080/10428194.2020.1827242
Klíčová slova Chronic myeloid leukemia; chronic phase; imatinib; dasatinib; second line; daily clinical practice
Popis To evaluate long-term real-life results of dasatinib therapy among chronic phase chronic myeloid leukemia patients resistant or intolerant to imatinib, we retrospectively analyzed data of 118 patients treated in centers participating in the database INFINITY. With median follow-up of 37 months, estimated 5-year cumulative incidences of complete cytogenetic and major molecular responses were 78% and 68%, respectively. The estimated 5-year probability of overall survival (OS) and event-free survival (EFS) were 86% and 83%, respectively. Both OS and EFS were significantly improved among patients withBCR-ABL1transcript level <= 10% at 3 months. Dasatinib toxicity was tolerable however persistent in almost half our patients, even after years of therapy. Pleural effusion occurred in 29% of patients and was responsible for 30% of dasatinib discontinuations. Our results confirmed very good efficacy and acceptable toxicity of dasatinib in second line setting and support the evidence and importance of high-quality real-life CML patient management.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info